IL193951A - A compound with central pyrrolidine units, an intermediate compound for the preparation of the mediated compound, a process for the production of the mediated compound, the use of a mediated compound for the manufacture of a drug, a pharmaceutical preparation, a method for the preparation of a pharmaceutical preparation, and a method for making conventional pharmaceutical salt of a non-salts compound. - Google Patents
A compound with central pyrrolidine units, an intermediate compound for the preparation of the mediated compound, a process for the production of the mediated compound, the use of a mediated compound for the manufacture of a drug, a pharmaceutical preparation, a method for the preparation of a pharmaceutical preparation, and a method for making conventional pharmaceutical salt of a non-salts compound.Info
- Publication number
- IL193951A IL193951A IL193951A IL19395108A IL193951A IL 193951 A IL193951 A IL 193951A IL 193951 A IL193951 A IL 193951A IL 19395108 A IL19395108 A IL 19395108A IL 193951 A IL193951 A IL 193951A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- bridged
- preparation
- pharmaceutical composition
- bridged compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1761—Apoptosis related proteins, e.g. Apoptotic protease-activating factor-1 (APAF-1), Bax, Bax-inhibitory protein(s)(BI; bax-I), Myeloid cell leukemia associated protein (MCL-1), Inhibitor of apoptosis [IAP] or Bcl-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78252306P | 2006-03-16 | 2006-03-16 | |
US87699406P | 2006-12-26 | 2006-12-26 | |
PCT/CA2007/000428 WO2007104162A1 (en) | 2006-03-16 | 2007-03-16 | Iap bir domain binding compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
IL193951A true IL193951A (en) | 2015-09-24 |
Family
ID=38509005
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL193951A IL193951A (en) | 2006-03-16 | 2008-09-07 | A compound with central pyrrolidine units, an intermediate compound for the preparation of the mediated compound, a process for the production of the mediated compound, the use of a mediated compound for the manufacture of a drug, a pharmaceutical preparation, a method for the preparation of a pharmaceutical preparation, and a method for making conventional pharmaceutical salt of a non-salts compound. |
Country Status (15)
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5230865B2 (ja) | 2004-07-15 | 2013-07-10 | テトラロジック ファーマシューティカルズ コーポレーション | Iap結合性化合物 |
EA019420B1 (ru) | 2004-12-20 | 2014-03-31 | Дженентех, Инк. | Пирролидиновые ингибиторы иап (ингибиторов апоптоза) |
EP1851200B1 (en) | 2005-02-25 | 2014-01-15 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
EP1883627B1 (en) | 2005-05-18 | 2018-04-18 | Pharmascience Inc. | Bir domain binding compounds |
US20100256046A1 (en) * | 2009-04-03 | 2010-10-07 | Tetralogic Pharmaceuticals Corporation | Treatment of proliferative disorders |
AU2006308453B9 (en) | 2005-10-25 | 2011-12-01 | Pharmascience Inc. | IAP BIR domain binding compounds |
KR20080080203A (ko) | 2005-12-19 | 2008-09-02 | 제넨테크, 인크. | Iap의 억제제 |
TWI504597B (zh) | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物 |
MX2008012053A (es) * | 2006-03-21 | 2008-12-17 | Joyant Pharmaceuticals Inc | Promotores de apoptosis de molecula pequeña. |
AU2007250443B2 (en) | 2006-05-16 | 2013-06-13 | Pharmascience Inc. | IAP BIR domain binding compounds |
WO2008014252A2 (en) * | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Iap inhibitors |
US20100144650A1 (en) * | 2006-07-24 | 2010-06-10 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
NZ574311A (en) * | 2006-07-24 | 2011-12-22 | Tetralogic Pharm Corp | Dimeric iap antagonists |
US8642554B2 (en) * | 2007-04-12 | 2014-02-04 | Joyant Pharmaceuticals, Inc. | Smac mimetic dimers and trimers useful as anti-cancer agents |
CA2683392A1 (en) * | 2007-04-30 | 2008-11-06 | Genentech, Inc. | Inhibitors of iap |
JP2010528587A (ja) * | 2007-05-07 | 2010-08-26 | テトラロジック ファーマシューティカルズ コーポレーション | アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてTNFα遺伝子の発現を用いる方法 |
US20100203012A1 (en) * | 2007-05-30 | 2010-08-12 | Aegera Therapeutics, Inc. | Iap bir domain binding compounds |
JP5658138B2 (ja) | 2008-04-23 | 2015-01-21 | ライジェル ファーマシューティカルズ, インコーポレイテッド | 代謝障害の処置のためのカルボキサミド化合物 |
WO2009136290A1 (en) * | 2008-05-05 | 2009-11-12 | Aegera Therapeutics, Inc. | Functionalized pyrrolidines and use thereof as iap inhibitors |
CA2728933A1 (en) * | 2008-06-27 | 2009-12-30 | Aegera Therapeutics Inc. | Bridged secondary amines and use thereof as iap bir domain binding compounds |
JP2011529962A (ja) * | 2008-08-02 | 2011-12-15 | ジェネンテック, インコーポレイテッド | Iapのインヒビター |
WO2010015090A1 (en) * | 2008-08-07 | 2010-02-11 | Aegera Therapeutics Inc. | Functionalized pyrrolidines and use thereof as iap inhibitors |
US20110177060A1 (en) * | 2008-09-19 | 2011-07-21 | Aegera Therapeutics, Inc. | Iap bir domain binding compounds |
US20100317593A1 (en) * | 2009-06-12 | 2010-12-16 | Astrazeneca Ab | 2,3-dihydro-1h-indene compounds |
US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
WO2011059763A2 (en) * | 2009-10-28 | 2011-05-19 | Joyant Pharmaceuticals, Inc. | Dimeric smac mimetics |
ES2625637T3 (es) | 2010-02-12 | 2017-07-20 | Pharmascience Inc. | Compuestos de unión al dominio BIR IAP |
UY33236A (es) | 2010-02-25 | 2011-09-30 | Novartis Ag | Inhibidores dimericos de las iap |
WO2012052758A1 (en) * | 2010-10-22 | 2012-04-26 | Astrazeneca Ab | Response biomarkers for iap antagonists in human cancers |
UY33794A (es) | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
US20160074515A1 (en) | 2014-06-20 | 2016-03-17 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
WO2020112855A1 (en) * | 2018-11-29 | 2020-06-04 | Reform Biologics, Llc | Excipient compounds for protein processing |
US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
CA2916970A1 (en) * | 2016-01-08 | 2017-07-08 | Pharmascience Inc. | A smac mimetic compound for use in the treatment of proliferative diseases |
CA3070992A1 (en) * | 2017-07-25 | 2019-01-31 | Hepagene Therapeutics, Inc. | Dimeric peptide inhibitors of apoptosis proteins |
CN117130035A (zh) * | 2017-08-18 | 2023-11-28 | 南京中硼联康医疗科技有限公司 | 生物剂量计及具有其的中子捕获治疗系统 |
JP2021523092A (ja) * | 2018-03-21 | 2021-09-02 | ピラマル・ファーマ・リミテッドPiramal Pharma Limited | アルファ−(ジアリールメチル)アルキルアミンの改良された不斉合成 |
JPWO2020027225A1 (ja) | 2018-07-31 | 2021-11-11 | ファイメクス株式会社 | 複素環化合物 |
CA3136106A1 (en) | 2019-04-05 | 2020-10-08 | Hepagene Therapeutics (HK) Limited | Bivalent antagonists of inhibitors of apoptosis proteins |
WO2020223403A1 (en) * | 2019-04-29 | 2020-11-05 | The Regents Of The University Of California | Anticancer smac derivatives |
EP4006037A4 (en) | 2019-07-31 | 2023-12-13 | Fimecs, Inc. | HETEROCYCLIC COMPOUND |
EP4093394A1 (en) | 2020-01-20 | 2022-11-30 | Astrazeneca AB | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
AU2022239717A1 (en) | 2021-03-15 | 2023-11-02 | Maze Therapeutics, Inc. | Inhibitors of glycogen synthase 1 (gys1) and methods of use thereof |
JP7260725B1 (ja) * | 2021-12-27 | 2023-04-18 | 株式会社トクヤマ | ペプチド製造方法、保護基の除去方法、及び除去剤 |
WO2023127331A1 (ja) * | 2021-12-27 | 2023-07-06 | 株式会社トクヤマ | ペプチド製造方法、保護基の除去方法、除去剤、及びベンジル化合物 |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US25347A (en) * | 1859-09-06 | Improvement | ||
US219140A (en) * | 1879-09-02 | Improvement in the art of ornamenting metallic foils | ||
US194741A (en) * | 1877-08-28 | Improvement in circular looms | ||
US207525A (en) * | 1878-08-27 | Improvement in car-coupling draw-bars | ||
US69812A (en) * | 1867-10-15 | Improved refrigerator | ||
US180828A (en) * | 1876-08-08 | Improvement in horse-powers | ||
US32437A (en) * | 1861-05-28 | Improvement in steam-plows | ||
US89896A (en) * | 1869-05-11 | Improvement in bee-hive | ||
US93428A (en) * | 1869-08-10 | Improvement in spurs for excelsior-machines | ||
US211627A (en) * | 1879-01-28 | Improvement in perforating-stamps | ||
US258581A (en) * | 1882-05-30 | husset | ||
US93429A (en) * | 1869-08-10 | Improvement in flasks for vulcanizing rubber plates for setting teeth | ||
JPH0680077B2 (ja) | 1985-02-08 | 1994-10-12 | サントリー株式会社 | プロリンエンドペプチダ−ゼインヒビタ−活性を有する新規ペプチド化合物 |
JPH04208299A (ja) | 1990-11-30 | 1992-07-29 | Ajinomoto Co Inc | プロリルエンドペプチターゼ阻害ペプチド |
US5817667A (en) * | 1991-04-17 | 1998-10-06 | University Of Georgia Research Foudation | Compounds and methods for the treatment of cancer |
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
AUPN727595A0 (en) * | 1995-12-22 | 1996-01-18 | Walter And Eliza Hall Institute Of Medical Research, The | Therapeutic compositions |
JP4208299B2 (ja) | 1998-08-19 | 2009-01-14 | 東レ株式会社 | 金属板貼合わせ成形加工用ポリエステルフィルム |
US6110691A (en) | 2000-01-06 | 2000-08-29 | Board Of Regents, The University Of Texas System | Activators of caspases |
US6608026B1 (en) | 2000-08-23 | 2003-08-19 | Board Of Regents, The University Of Texas System | Apoptotic compounds |
US6992063B2 (en) | 2000-09-29 | 2006-01-31 | The Trustees Of Princeton University | Compositions and method for regulating apoptosis |
WO2004007529A2 (en) | 2002-07-15 | 2004-01-22 | The Trustees Of Princeton University | Iap binding compounds |
AU2001293189A1 (en) | 2000-09-29 | 2002-04-08 | Trustees Of Princeton University | Compositions and methods for regulating apoptosis |
WO2002030959A2 (en) | 2000-10-13 | 2002-04-18 | Abbott Laboratories | Peptides derived from smac (diablo) and methods of use therefor |
JP2004536079A (ja) * | 2001-05-16 | 2004-12-02 | アンテックスファーマ・インコーポレーテッド | 置換1−ベンズアゼピンおよびその誘導体 |
EP1421204A4 (en) | 2001-05-31 | 2004-12-15 | Univ Princeton | PEPTIDES BINDING TO THE IAP INHIBITOR AND ASSAYS FOR IDENTIFYING COMPOUNDS THAT BIND TO THE IAP INHIBITOR |
AU2002314165B2 (en) * | 2001-06-19 | 2008-02-21 | Altana Pharma Ag | Tryptase inhibitors |
US20060258581A1 (en) | 2001-11-21 | 2006-11-16 | Reed John C | Methods and composition for derepressions of IAP-inhibited caspase |
WO2003086470A2 (en) | 2002-04-17 | 2003-10-23 | Deutsches Krebsforschungszentrum | Smac-peptides as therapeutics against cancer and autoimmune diseases |
AU2003249920A1 (en) * | 2002-07-02 | 2004-01-23 | Novartis Ag | Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap) |
FR2844271A1 (fr) * | 2002-09-09 | 2004-03-12 | Oreal | Derives bis-paraphenylenediamine a groupement pyrrolidinyle et utilisation de ces derives pour la coloration de fibres keratiniques |
DE60334247D1 (de) | 2002-11-27 | 2010-10-28 | Irm Llc | Verfahren und zusammensetzungen zur apoptoseinduktion in krebszellen |
WO2004066958A2 (en) | 2003-01-30 | 2004-08-12 | The Trustees Of Princeton University | Caspase-9:bir3 domain of xiap complexes and methods of use |
US7067274B2 (en) * | 2003-11-13 | 2006-06-27 | Genentech, Inc. | Compositions and methods for the screening pro-apoptotic compounds |
JP2007523061A (ja) | 2004-01-16 | 2007-08-16 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Smacペプチドミメティクスおよびその使用法 |
BRPI0507482A (pt) | 2004-02-05 | 2007-07-17 | Novartis Ag | combinação de (a) um inibidor de dna topoisomerase e (b) um inibidor de iap |
JP4674231B2 (ja) * | 2004-03-01 | 2011-04-20 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 2量体小分子アポトーシス増強剤 |
US7345081B2 (en) | 2004-03-23 | 2008-03-18 | Genentech, Inc. | Azabicyclo-octane inhibitors of IAP |
EP2253614B1 (en) | 2004-04-07 | 2012-09-19 | Novartis AG | Inhibitors of IAP |
US7244851B2 (en) | 2004-07-02 | 2007-07-17 | Genentech, Inc. | Inhibitors of IAP |
US7674787B2 (en) | 2004-07-09 | 2010-03-09 | The Regents Of The University Of Michigan | Conformationally constrained Smac mimetics and the uses thereof |
BRPI0513310A (pt) | 2004-07-12 | 2008-05-06 | Idun Pharmaceuticals Inc | análogos de tetrapeptìdeo |
JP5230865B2 (ja) | 2004-07-15 | 2013-07-10 | テトラロジック ファーマシューティカルズ コーポレーション | Iap結合性化合物 |
EA019420B1 (ru) | 2004-12-20 | 2014-03-31 | Дженентех, Инк. | Пирролидиновые ингибиторы иап (ингибиторов апоптоза) |
EP1851200B1 (en) * | 2005-02-25 | 2014-01-15 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
US20070003535A1 (en) | 2005-03-17 | 2007-01-04 | Reed John C | Methods and compositions for derepression of IAP-inhibited caspase |
DE102005017116A1 (de) | 2005-04-13 | 2006-10-26 | Novartis Ag | Hemmstoffe für Inhibitoren von Apoptose Proteinen (IAP) |
EP1883627B1 (en) | 2005-05-18 | 2018-04-18 | Pharmascience Inc. | Bir domain binding compounds |
AU2006254538A1 (en) | 2005-05-25 | 2006-12-07 | 2Curex Aps | Compounds modifying apoptosis |
MX2007015419A (es) | 2005-06-08 | 2008-02-21 | Novartis Ag | Compuestos organicos. |
JP2009509128A (ja) * | 2005-08-09 | 2009-03-05 | テトラロジック ファーマシューティカルズ コーポレーション | 増殖性疾患の治療 |
AU2006308453B9 (en) | 2005-10-25 | 2011-12-01 | Pharmascience Inc. | IAP BIR domain binding compounds |
KR20080080203A (ko) | 2005-12-19 | 2008-09-02 | 제넨테크, 인크. | Iap의 억제제 |
JP5227805B2 (ja) | 2005-12-20 | 2013-07-03 | ノバルティス アーゲー | Iap阻害剤とタキサン7の組合せ剤 |
WO2007101347A1 (en) | 2006-03-07 | 2007-09-13 | Aegera Therapeutics Inc. | Bir domain binding compounds |
TWI504597B (zh) | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物 |
MX2008012053A (es) | 2006-03-21 | 2008-12-17 | Joyant Pharmaceuticals Inc | Promotores de apoptosis de molecula pequeña. |
CN101484151B (zh) | 2006-05-05 | 2012-11-21 | 密执安州立大学董事会 | 二价smac模拟物及其应用 |
AU2007250443B2 (en) | 2006-05-16 | 2013-06-13 | Pharmascience Inc. | IAP BIR domain binding compounds |
WO2008014238A2 (en) | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
WO2008014252A2 (en) | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Iap inhibitors |
WO2008014236A1 (en) | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
US20100144650A1 (en) | 2006-07-24 | 2010-06-10 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
WO2008014240A2 (en) | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
NZ574311A (en) | 2006-07-24 | 2011-12-22 | Tetralogic Pharm Corp | Dimeric iap antagonists |
PE20110220A1 (es) | 2006-08-02 | 2011-04-11 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
BRPI0719221A2 (pt) | 2006-10-12 | 2014-03-18 | Novartis Ag | Derivados de pirrolidina como inibidores de iap |
JP2010507096A (ja) | 2006-10-19 | 2010-03-04 | ノバルティス アーゲー | 有機化合物 |
CA2670498A1 (en) | 2006-11-28 | 2008-06-05 | Novartis Ag | Combination of iap inhibitors and flt3 inhibitors |
WO2008085610A1 (en) | 2006-11-28 | 2008-07-17 | Novartis Ag | Use of iap inhibitors for the treatment of acute myeloid leukemia |
BRPI0720049A2 (pt) | 2006-12-07 | 2014-01-07 | Novartis Ag | Derivados de piridina utilizados como inibidores de xiap |
JP2010513561A (ja) | 2006-12-19 | 2010-04-30 | ジェネンテック, インコーポレイテッド | Iapのイミダゾピリジンインヒビター |
US8642554B2 (en) | 2007-04-12 | 2014-02-04 | Joyant Pharmaceuticals, Inc. | Smac mimetic dimers and trimers useful as anti-cancer agents |
CN101686981B (zh) | 2007-04-13 | 2013-04-10 | 密执安州立大学董事会 | 重氮双环类smac模拟物及其用途 |
CA2683392A1 (en) | 2007-04-30 | 2008-11-06 | Genentech, Inc. | Inhibitors of iap |
US20100203012A1 (en) | 2007-05-30 | 2010-08-12 | Aegera Therapeutics, Inc. | Iap bir domain binding compounds |
EP2058312A1 (en) | 2007-11-09 | 2009-05-13 | Universita' degli Studi di Milano | SMAC mimetic compounds as apoptosis inducers |
-
2007
- 2007-03-15 TW TW096108935A patent/TWI504597B/zh not_active IP Right Cessation
- 2007-03-15 TW TW103145747A patent/TWI543988B/zh not_active IP Right Cessation
- 2007-03-16 JP JP2008558611A patent/JP5419468B2/ja not_active Expired - Fee Related
- 2007-03-16 KR KR1020087025218A patent/KR101446907B1/ko not_active IP Right Cessation
- 2007-03-16 BR BRPI0709610-0A patent/BRPI0709610A2/pt not_active IP Right Cessation
- 2007-03-16 MX MX2008011837A patent/MX2008011837A/es active IP Right Grant
- 2007-03-16 NZ NZ571577A patent/NZ571577A/en not_active IP Right Cessation
- 2007-03-16 CA CA2581960A patent/CA2581960C/en not_active Expired - Fee Related
- 2007-03-16 EP EP07710756A patent/EP2004600A4/en not_active Withdrawn
- 2007-03-16 AU AU2007224932A patent/AU2007224932B2/en not_active Ceased
- 2007-03-16 US US11/723,044 patent/US7579320B2/en not_active Expired - Fee Related
- 2007-03-16 SG SG201101952-8A patent/SG170739A1/en unknown
- 2007-03-16 WO PCT/CA2007/000428 patent/WO2007104162A1/en active Application Filing
- 2007-11-01 US US11/979,280 patent/US7645741B2/en not_active Expired - Fee Related
-
2008
- 2008-09-07 IL IL193951A patent/IL193951A/en not_active IP Right Cessation
- 2008-09-09 NO NO20083868A patent/NO20083868L/no not_active Application Discontinuation
-
2009
- 2009-11-17 US US12/619,979 patent/US20100221261A1/en not_active Abandoned
-
2012
- 2012-11-08 US US13/672,637 patent/US8765681B2/en not_active Expired - Fee Related
-
2014
- 2014-05-23 US US14/285,841 patent/US9365614B2/en not_active Expired - Fee Related
- 2014-10-28 PH PH12014502420A patent/PH12014502420A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
US8765681B2 (en) | 2014-07-01 |
CA2581960A1 (en) | 2007-09-16 |
US20140336134A1 (en) | 2014-11-13 |
KR20080112304A (ko) | 2008-12-24 |
MX2008011837A (es) | 2009-02-10 |
TWI504597B (zh) | 2015-10-21 |
NO20083868L (no) | 2008-11-06 |
AU2007224932B2 (en) | 2013-05-23 |
US20080207525A1 (en) | 2008-08-28 |
RU2008140935A (ru) | 2010-04-27 |
US20100221261A1 (en) | 2010-09-02 |
TW200800961A (en) | 2008-01-01 |
SG170739A1 (en) | 2011-05-30 |
JP5419468B2 (ja) | 2014-02-19 |
EP2004600A1 (en) | 2008-12-24 |
BRPI0709610A2 (pt) | 2011-07-19 |
US20080069812A1 (en) | 2008-03-20 |
PH12014502420B1 (en) | 2015-11-16 |
KR101446907B1 (ko) | 2014-10-06 |
TW201538520A (zh) | 2015-10-16 |
US9365614B2 (en) | 2016-06-14 |
US20130071411A1 (en) | 2013-03-21 |
NZ571577A (en) | 2011-09-30 |
US7645741B2 (en) | 2010-01-12 |
CA2581960C (en) | 2015-11-24 |
EP2004600A4 (en) | 2012-05-02 |
AU2007224932A1 (en) | 2007-09-20 |
JP2009529544A (ja) | 2009-08-20 |
US7579320B2 (en) | 2009-08-25 |
TWI543988B (zh) | 2016-08-01 |
PH12014502420A1 (en) | 2015-11-16 |
WO2007104162A1 (en) | 2007-09-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL193951A (en) | A compound with central pyrrolidine units, an intermediate compound for the preparation of the mediated compound, a process for the production of the mediated compound, the use of a mediated compound for the manufacture of a drug, a pharmaceutical preparation, a method for the preparation of a pharmaceutical preparation, and a method for making conventional pharmaceutical salt of a non-salts compound. | |
IL194871A (en) | Compound linking to bir iap site, intermediate compound, process for compound preparation, method for making acceptable pharmaceutical salt, pharmaceutical preparation and use of compound for drug production | |
IL210577A (en) | Compound 1,2,3,4-tetrahydrocyclopenta [b] indole-3-yl acetic acid, salt, hydrate and solvent, pharmaceutical, compound, salt, hydrate, solvent or pharmaceutical for use as a medicine or treatment Salt, hydrate, solvent or pharmaceutical preparation in the manufacture of a drug and process for the preparation | |
IL250439A0 (en) | Use of fingolimod, or a phosphate derivative thereof or a pharmaceutical acceptable salt thereof for the preparation of a drug for the treatment of multiple sclerosis | |
EP2054416B8 (en) | Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine | |
EP2086945A4 (en) | NOVEL PROCESS FOR THE PRODUCTION OF STATINES AND THEIR PHARMACEUTICAL ACCEPTIC SALTS | |
IL195788A (en) | Vegf Antagonist Vascular Endothelial Growth Factor, a method of preparation and an appropriate intravenous injection containing them | |
ZA201001015B (en) | (Carboxylalkylene-phenyl)-phenyl-oxalamides, method for the production thereof, and use of same as a medicament | |
IL204556A (en) | (Cyclopropyl - phenyl) - Phenyl - oxalamides, a method for their production, and their use as a drug | |
WO2007144169A3 (en) | Entacapone-derivatives | |
IL188643A (en) | Derivatives – n (troaryl) –1 – troarylalkyl – 1h – indole – 2– carboxamide, process for the production of derivatives, drug, pharmaceutical composition and use of derivatives for drug production. | |
EP2133060A4 (en) | METHOD FOR PRODUCING PREPARATION FOR ORAL ADMINISTRATION | |
IL212966A (en) | Pyrazole-1-yl-methyl-cyclohexyl-acetic acid compounds, pharmaceutical preparations containing them, use of pharmaceutical preparation compounds and compounds for use in treatment method | |
WO2010070677A3 (en) | A process for the preparation of prasugrel and its pharmaceutically acceptable salts thereof | |
HK1114516A1 (en) | Substituted sulfoxide compounds, methods for preparing the same and use thereof | |
WO2010012459A3 (en) | A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms | |
WO2011131370A8 (en) | Melt-granulated fingolimod | |
WO2010046932A3 (en) | Extended release pharmaceutical composition of minocycline and process thereof | |
PL2291374T3 (pl) | Sposób wytwarzania solifenacyny i/lub jej farmaceutycznie dopuszczalnych soli o wysokiej czystości farmaceutycznej | |
WO2008034912A3 (en) | Process for the synthesis of clopidogrel and new forms of pharmaceutically acceptable salts thereof | |
PL1589014T3 (pl) | Sposób syntezy pochodnych 1,3-dihydro-2H-3-benzazepin-2-onu i jego zastosowanie do wytwarzania iwabradyny i jej dopuszczalnych farmaceutycznie soli | |
ATE500226T1 (de) | Aripiprazolhemifumarat und verfahren zu dessen herstellung | |
WO2009125975A3 (ko) | 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법 | |
HK1147758A1 (US08039623-20111018-C00020.png) | ||
WO2009080745A3 (de) | Perhydrochinoxalin-derivate als analgetika |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |